DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Angina pectoris (Cont.):
variant (Prinzmetal’s), 751, 752
calcium channel antagonists for,
766
nitrates for, 761
treatment of, 761
Angioedema
ACE inhibitors and, 736, 932
androgen treatment of, 1204
H 1
receptor antagonists for, 922
kinins and, 931
Angiogenesis
definition of, 1738
inhibitors, 1738–1740
mechanism of efficacy of, 1738
toxicity of, 1739–1740
Angiogenic factors, 1738
ANGIOMAX (bivalirudin), 859–860
Angiotensin, biosynthesis, alternative
pathways for, 726
Angiotensin (1-7), 725
Angiotensin (3-8), 725
Angiotensinases, 725
Angiotensin converting enzyme, 721,
724–725
Angiotensin converting enzyme 2, 725
Angiotensin-converting enzyme
(ACE), 722f, 927f, 929
Angiotensin-converting enzyme (ACE)
inhibitors, 730, 731–736,
731f, 926, 927f, 931,
932–933
acute renal failure caused by, 736
adverse effects and side effects of,
798
adverse effects of, 735–736
angioedema caused by, 736
clinical pharmacology of, 731–734
for congestive heart failure, 793
cough caused by, 735–736
drug interactions with, 736
dysgeusia caused by, 736
effects on renin-angiotensin system,
746t
fetopathic potential of, 736
glycosuria caused by, 736
hepatotoxicity, 736
history of, 721, 731
hyperkalemia caused by, 736
hypoglycemia and, 1248t
hypotension caused by, 735
mechanism of action of, 797
neutropenia caused by, 736
pharmacological effects in normal
animals and humans, 731
Angiotensin-converting enzyme (ACE)
inhibitors (Cont.):
skin rash caused by, 736
structure of, 732f
therapeutic uses of
for heart failure, 797–798
survival rates with, 798
for hypertension, 734
in left ventricular dysfunction,
734–735
in myocardial infarction, 735
in patients at high risk of
cardiovascular events, 735
in progressive renal impairment,
735
in scleroderma renal crisis, 735
Angiotensin converting enzyme (ACE)
inhibtors, polymorphisms
and response to, 159t, 160t
Angiotensin converting enzyme (ACE)
polymorphisms, 160t
Angiotensin-converting enzyme
inhibitors (ACEI), 753. See
also specific agent
as antihypertensive agents, 774t,
784–785
drug interactions with, 976
hemodynamic effects of, with longterm
administration, 774t
Angiotensin I, 721, 722f, 927f
Angiotensin II, 721, 722f, 797, 927f
and aldosterone release from adrenal
cortex, 729
and altered cardiovascular structure,
730
and altered renal hemodynamics,
729–730
and catecholamine release from
adrenal medulla, 729
CNS effects of, 729
and direct vasoconstriction, 728–729
effects on blood pressure, 727f
effects on cardiovascular structure,
mechanisms, 728f
effects on peripheral resistance,
mechanisms, 728f
effects on renal blood flow, 727f
effects on renal function, 729f
mechanisms, 728f
enhancement of peripheral
noradrenergic
neurotransmission, 729
functions of, 727–728
rapid pressor response to, 727–729
and renal function, 729
Angiotensin II (Cont.):
slow pressor response to, 728
and sodium reabsorption in renal
tubules, 729
and vasopressin secretion, 704
Angiotensin III, 725
Angiotensin II receptor antagonist(s),
730, 731f, 736–745
adverse effects and side effects of,
785–786
adverse effects of, 745
as antihypertensive agents, 774t,
785–786
clinical pharmacology of, 738
for congestive heart failure, 793
effects on renin-angiotensin system,
746t
hemodynamic effects of, with longterm
administration, 774t
history of, 736
pharmacological properties of,
736–738
precautions with, 785–786
structure of, 737f
therapeutic uses of, 738–745, 786
Angiotensin II receptor antagonists,
105t, 110
for heart failure, 798–799
Angiotensin IV, 725
Angiotensinogen, 721, 722f, 724
Angiotensin peptides, 725
Angiotensin receptor(s), 726–727, 797
Angiotensin receptor-effector
coupling, 727
Angiotonin, 721
Anidulafungin, 1584–1585
Animal testing, descriptive toxicity, 78
Anisocoria, 1776
diagnosis of, 1793
Ankylosing spondylitis (AS),
biological agents for, 1825t
Annexins, 941
Anorexia, warfarin-induced, 864
Anovulation, 1841
ANS. See Autonomic nervous system
(ANS)
ANSAID (flurbiprofen), 989
Antacids, 1315–1316, 1316t
ANTAGON (ganirelix), 1119t, 1843
Antagonism, 77–78
Antazoline, for ophthalmic use, 1789
Anterior chamber (ocular), 1774, 1776f
Anthracenedione, for neoplastic
disease, 1668t–1670t,
1713–1715
1997
INDEX